
The author describes how Merrion Pharmaceuticals reformulates parenteral drugs into tablets and capsules that are easier for patients to take and provide better bioavailability.

The author describes how Merrion Pharmaceuticals reformulates parenteral drugs into tablets and capsules that are easier for patients to take and provide better bioavailability.

The author details the factors in formulation design, requirements in facilites and equipment, and validation criteria for aseptic formualtions.

A Conversation with Greystone Associates' George Perros. This article contains bonus online-exclusive material.

The author discusses the risks involved with aseptic processing, methods and tools used to identify and control risk, and regulatory guidelines relevant to the risk-management process.

A Conversation with Otonomy

According to a survey conducted by Pharmaceutical Technology Europe (PTE), almost 50% of you believe that cost is the biggest limiting factor to innovation in the pharmaceutical packaging industry.

Following years of development, DataMatrix codes are now a viable labelling solution for pharma manufacturers.

Michael Rubenstein, Chief Growth and Innovation Officer at Alcan Packaging, talks about applying a philosophy of sustainability to the pharmaceutical packaging supply chain.

Population ageing is an issue often discussed in the media, but its impact on all facets of life has been poorly characterized.

In 2010, Braille embossing will be required on all European pharmaceutical packages. Is the industry ready?

Apopular definition of insanity is repeating the same task over and over again while expecting a different result. It would appear, therefore, that many people in the contract services industry think the major global bio/pharma companies are insane.

What trends have you witnessed in the pharmaceutical packaging industry in the last 2 years?

Paper is no longer a sufficient format for information storage and interchange in the pharmaceutical industry; documents are inflexible and costly for production and storage.

Researchers at the University of Leicester (UK) have combined crime research and space-age technology to create a new method of detecting counterfeit pharmaceuticals. The technique, Spectral ID, works by detecting the differences between the characteristics of light reflected from printed packaging.

Mark Copley discusses the methods used for DPI testing and the challenges presented by the current regulatory framework.

With counterfeit drugs on the rise, the Chairman and CEO of Ahura Scientific discusses the issue and explains how a handheld device is helping companies to tackle the problem.

Cargill has recently announced a number of innovations connected to its range of polyol excipients.

An inhaler mouthpiece that optimizes drug delivery to the lungs and reduces the amount of wasted medication has been developed by US researchers.

Also, Astellas and Medivation sign development pact; WuXi PharmaTech appoints VP of business development, more...

The US Food and Drug Administration is using prescription data from Wolters Kluwer Pharma Solutions to track the treatment of influenza A (H1N1) and other influenza viruses, according to a statement that the company released last week.

New barcoding technologies are helping to aid product traceability and fight counterfeits. Mark Beauchamp of Citizen Systems Europe explains how.

The European Fine Chemicals Group (EFCG) gave an update of some of its activities at a press conference held at CPhI Worldwide (Spain) last week, and revealed some disturbing facts regarding counterfeit APIs, which the group is particularly concerned about.

The US Food and Drug Administration issued a guidance for industry and review staff titled, Labeling for Human Prescription Drug and Biological Products-Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information.

Company and People Notes: SurModics forms agreement with Roche and Genentech; Hospira names Daphne Jones senior VP and chief information officer; more...

Following the completion of its $68-billion acquisition of Wyeth (Madison, NJ), Pfizer (New York) began joint operations of the combined company last week.